Boston Scientific (NYSE:BSX) Sets New 1-Year Low After Analyst Downgrade

Key Points

• Boston Scientific shares fell to a new 52-week low, trading as low as $39.57 after Needham cut its price target from $57 to $48, though it maintained a buy rating.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $65.63; insiders have also purchased roughly $9.4 million of company stock over the past 90 days.
• Despite third-quarter earnings and revenue slightly beating estimates, cybersecurity-related disruptions and weaker guidance led Boston Scientific to reduce its 2026 outlook and forecast a 1%–3% fourth-quarter sales decline.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) shares hit a new 52-week low during trading on Wednesday after Needham & Company LLC lowered their price target on the stock from $57.00 to $48.00. Needham & Company LLC currently has a buy rating on the stock. Boston Scientific traded as low as $39.57 and last traded at $43.0990, with a volume of 35,453,115 shares trading hands. The stock had previously closed at $45.06.

Several other equities research analysts have also recently weighed in on the stock. Leerink Partners lowered their price objective on shares of Boston Scientific from $60.00 to $55.00 in a research report on Friday, October 9th. TD Cowen reiterated a "buy" rating on shares of Boston Scientific in a research report on Tuesday, October 20th. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Wells Fargo & Company dropped their target price on Boston Scientific from $50.00 to $48.00 and set an "equal weight" rating for the company in a research report on Wednesday, September 23rd. Finally, The Goldman Sachs Group cut their price target on Boston Scientific from $71.00 to $57.00 and set a "buy" rating on the stock in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus target price of $65.63.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter adjusted earnings of $0.73 per share, slightly above the $0.72 consensus estimate, while revenue of $5.138 billion also exceeded expectations of approximately $5.06 billion. Boston Scientific third-quarter earnings report
• Positive Sentiment: Management highlighted longer-term potential, targeting a business-cycle trough in 2027 and expansion toward 2030. The company also began enrollment in its Elite AF clinical trial and received FDA clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Boston Scientific third-quarter results announcement
• Neutral Sentiment: Third-quarter reported sales increased 1.5% year over year to $5.138 billion, but adjusted EPS declined from $0.75 to $0.73 and GAAP EPS fell from $0.51 to $0.40. Cardiovascular sales rose 1.9%, while MedSurg sales grew only 0.6%; regional performance was mixed.
• Negative Sentiment: Boston Scientific again reduced its fiscal-year 2026 outlook after a cybersecurity incident disrupted operations and weighed on demand. Management now expects approximately 4.25% reported sales growth for the year and forecasts fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific outlook and cybersecurity report
• Negative Sentiment: The cybersecurity fallout, other operating headwinds and lower guidance overshadowed the earnings and revenue beats. The stock was trading near its 52-week low and below both its 50-day and 200-day moving averages, reflecting continued investor concern about near-term execution and growth.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Parcion Private Wealth LLC acquired a new stake in shares of Boston Scientific during the third quarter worth $680,000. Soltis Investment Advisors LLC boosted its position in shares of Boston Scientific by 136.3% during the 3rd quarter. Soltis Investment Advisors LLC now owns 14,865 shares of the medical equipment provider's stock valued at $649,000 after purchasing an additional 8,573 shares in the last quarter. Financial Solutions Advisory Group Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $1,123,000. Choreo LLC grew its stake in Boston Scientific by 12.8% during the third quarter. Choreo LLC now owns 43,410 shares of the medical equipment provider's stock worth $1,895,000 after purchasing an additional 4,937 shares during the period. Finally, Interchange Capital Partners LLC acquired a new stake in Boston Scientific during the third quarter worth approximately $209,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a fifty day simple moving average of $45.29 and a two-hundred day simple moving average of $57.71. The firm has a market capitalization of $62.76 billion, a P/E ratio of 17.54, a P/E/G ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, beating the consensus estimate of $0.72 by $0.01. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.06 billion. During the same period last year, the business posted $0.75 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Corporation will post 3.21 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.